Lenacapavir inhibits the virus’s ability to replicate within cells.
It has now cleared the initial phase I testing obstacle and has the potential to become the longest-acting HIV prevention method if additional trials proceed as planned.
To lower their risk, patients can now take daily pills or occasionally receive injections every eight weeks as part of pre-exposure prophylaxis (PrEP).
Although PrEP medications are incredibly effective, it can be challenging to take them daily.
According to the most recent estimates, 39.9 million individuals have HIV in 2023, with 65% of those living in the WHO African Region.
Additionally, plans to eradicate the HIV epidemic by 2030 are being developed by the WHO, Global Fund, and Joint United Nations Programme on HIV and Aids (UNAids).
